Lantheus shares are trading higher possibly after Eli Lilly agreed to acquire POINT Biopharma. Lantheus and POINT are partners for certain cancer programs.
Portfolio Pulse from Benzinga Newsdesk
Lantheus shares are trading higher after Eli Lilly agreed to acquire POINT Biopharma. Lantheus and POINT are partners for certain cancer programs.
October 03, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lantheus shares are trading higher due to Eli Lilly's acquisition of POINT Biopharma, a partner of Lantheus in certain cancer programs.
The acquisition of POINT Biopharma by Eli Lilly, a partner of Lantheus in certain cancer programs, is likely to have a positive impact on Lantheus' stock price in the short term. This is because the acquisition could potentially strengthen the cancer programs that Lantheus and POINT are partners in, thereby increasing Lantheus' potential revenues and profitability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100